<DOC>
	<DOCNO>NCT00854451</DOCNO>
	<brief_summary>The aim study ( 1 ) evaluate prevalence rate PM CYP2C19 country ; ( 2 ) evaluate efficacy dual therapy different dose omeprazole amoxicillin ; ( 3 ) judge relationship genotype CYP2C19 eradication rate dual therapy peptic ulcer patient ; ( 4 ) try find predictor success dual therapy optimal dose dual therapy first-line rescue anti-Helicobacter pylori regimen .</brief_summary>
	<brief_title>Relation Metabolic Rate Omeprazole Eradication Helicobacter Pylori Infection</brief_title>
	<detailed_description>Anti-H. pylorus therapy recommend patient peptic ulcer disease associate bacterial infection . Dual therapy contain one PPI amoxicillin suggest well treatment classical triple therapy contain bismuth , metronidazole , tetracycline H. pylorus eradication due good compliance few side effect . However , variation eradication rate among different study limit clinical application . Nonetheless , amoxicillin-based dual therapy , rare prevalence primary secondary antibiotic resistance , potential optimal first-line rescue anti-Helicobacter pylori regimen confound factor cause labile treatment outcome clarify . Cytochrome P450 2C19 ( CYP2C19 ) , enzyme metabolizes omeprazole , find genetic polymorphism enzyme activity . The percentage poor metabolizer ( PM ) CYP2C19 much high Oriental ( 18~23 % ) comparing Caucasian ( 3~5 % ) . The aim study try find predictor success dual therapy optimal dose dual therapy first-line rescue anti-Helicobacter pylori regimen . About 130 patient Hp positive duodenal ulcer enrol allocate randomly one four treatment group : Group A：omeprazole 20mg bid 2wk + amoxicillin 500mg qid 2wk ; Group B：omeprazole 20mg bid 2wk + amoxicillin 250mg qid 2wk ; Group C：omeprazole 20mg qd 2wk + amoxicillin 500mg qid 2wk ; Group D：omeprazole 20mg qd 2wk + amoxicillin 250mg qid 2wk . All patient receive endoscopic exam biopsy within 1~2 month end treatment . The status H. pylori infection examine endoscopy 13C-urea breath test ( patient refuse second endoscopy ) . Biopsy antrum body take culture , histology CLO test . Twenty-four hour intragastric pH measurement perform 6 randomly selective patient group patient complete first week course treatment . PCR-RFLP method use detect genotype CYP2C19 polymorphism use genomic DNA extract whole blood 130 treat patient . The genotyping result correlate H. pylori eradication rate intragastric pH value . The equivalence demographic information among various treatment group genotype reveal chi-square independence test , t-test , one-way ANOVA , Kruskal-Wallis test . The statistical method well Mann-Whitney test also use analyze clinical outcome . Confidence interval eradication rate compute plus-four method . Multiple logistic regression use explore predictor eradication outcome . Multiple regression use explore predictor intragastric acidity . A p-value le 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Male female dyspeptic patient H. pyloripositive duodenal ulcer . Pregnant nursing woman Serious concomitant illness Malignant tumor kind Serious bleed course ulcer Previous gastric surgery Taking bismuth compound , proton pump inhibitor , antibiotic nonsteroid antiinflammatory drug least one month prior pretreatment endoscopy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 1996</verification_date>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>CYP2C19 genotype</keyword>
	<keyword>intragastric pH</keyword>
	<keyword>dual therapy</keyword>
	<keyword>antibiotic resistance</keyword>
</DOC>